Monday, October 19, 2026 from 1:45 p.m. to 5:00 p.m. MDT at Salt Palace Convention Center - Ballroom E
This session is being recorded.
Learn MoreThe Clinical Reasoning Series aims to deliver programs that meaningfully advance pharmacy specialists’ knowledge, skills, and clinical judgment. Topic selection for the program reflects content that is timely and of relevance and value to the practice of Board Certified Pharmacotherapy Specialists (BCPS).
Participants will have the opportunity to attend four educational activities, divided into two-part morning and two-part afternoon sessions. Part One will offer 3.0 contact hours of continuing pharmacy education credit toward BCPS recertification credit upon completing the required posttests by the submission deadline and achieving a predetermined passing score. The posttests will be available on November 11, 2026. The deadline to submit posttests and earn recertification credit for the session will be November 11, 2027. If you have not already purchased posttest access and wish to add it to your registration, email [email protected] or visit the registration desk on or before October 20, 2026.
 | | Moderator: | Paul M. Boylan, Pharm.D., BCPS | | Associate Professor
The University of Oklahoma College of Pharmacy
Oklahoma City, OK | | View Biography |
|
Sex, Drugs, and Risk Reduction: Discussing and Debating Estrogen and Testosterone in 20261:45 p.m. to 3:15 p.m.
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-26-112-L01-P
Activity Type: An Application-Based Activity
Hormone therapy is a cornerstone to manage menopause and age-related hypogonadism; however, decades of conflicting evidence and regulatory warnings have paralyzed board certified clinical pharmacists aiming to balance symptom management against uncertain risks. In 2025, the Food and Drug Administration changed estrogen prescribing information and signaled similar revisions for testosterone, fundamentally altering the narrative that has dominated clinical pharmacy practice since the 1970s and conflicts with the positions of professional organizations in gynecology, endocrinology, and sexual health. Using clinical reasoning sessions (Spilling the T about Testosterone Therapy and Menopausal Hormone Therapy – Is There New Evidence or Just Re-Interpretation?) and an interactive expert panel format, this application-based continuing pharmacy education program addresses a critical gap between board certified pharmacists’ expertise and their ability to critically appraise – without bias or persuasion – conflicting hormone therapy evidence, communicate risk measures, and synthesize evidence from reliable resources to create person centered care plans. This activity will offer 1.5 contact hours of CPE and BCPS recertification credit. Learning Objectives1. Critique key historical studies contributing to conflicting perspectives on cardiovascular risk with testosterone therapy. 2. Reconcile discordance between public policy and clinical practice guidelines on testosterone therapy with emerging literature. 3. Formulate evidence-based and patient-centered testosterone therapy recommendations reflective of the latest evidence on cardiovascular risks and benefits. 4. Compare the results and context of the original Women’s Health Initiative studies to the application of studies today. 5. Organize a list of indications for menopausal hormone therapy based on the strength of evidence to support the indications. 6. Given patient specific menopausal symptoms, design an evidence-based person-centered care plan for symptom control.  | | Speaker: | Jimmy Gonzalez, Pharm.D., MPH, BCPS | | Clinical Associate Professor
Rutgers, The State University of New Jersey
Piscataway, NJ | | View Biography |
|  | | Speaker: | Karen M. Gunning, Pharm.D., B.S.Pharm, FCCP, BCACP, BCPS | | Professor (Clinical) of Pharmacotherapy
Associate Dean
The University of Utah College of Pharmacy
Salt Lake City, Utah | | View Biography |
|
|
Break in Programming3:15 p.m. to 3:30 p.m. |
Heated Rival-Rx: Opportunities and Interventions in Sports Pharmacy3:30 p.m. to 5:00 p.m.
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-26-113-L01-P
Activity Type: An Application-Based Activity
Athletes and physically active patients increasingly seek pharmacist expertise for medication and supplement management while health systems and academic institutions are creating dedicated sports pharmacist positions and microcredentials to serve collegiate and professional sports organizations. Although BCPS practitioners possess strong clinical expertise, many might lack specialized knowledge needed for athlete-specific decisions, including anti-doping compliance, performance-enhancing substance evaluation, therapeutic use exemptions, and medication optimization aligned with training and competition schedules. This application-based session will summarize key fundamental anti-doping rules and resources for pharmacists and use case-based exercises and discussions to address potential scenarios that clinical pharmacists might encounter when caring for athlete-patients facing specific physiologic demands, performance goals, and regulatory requirements. This activity offers 1.5 contact hours of CPE and BCPS recertification credit. Learning Objectives1. Interpret key anti-doping rules relevant to clinical pharmacists. 2. Describe athlete experiences and expectations surrounding anti-doping regulations. 3. Evaluate use of prohibited substances and methods. 4. Show resources available to pharmacists providing care to athlete-patients. 5. Assess how pharmacists can help athletes apply for therapeutic use exemptions. 6. Recommend appropriate supplement use for athletes through evidence-based evaluation of risks and benefits.  | | Speaker: | Marina Suzuki, Pharm.D., Ph.D., BCACP, BCPS | | Health Economics Research Manager
Washington State Health Care Authority
Olympia, WA | | View Biography |
|
|